A Wednesday night earnings report left big questions about how the spending reductions would affect the company.

Biotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million.

Genomics is bringing in a new wave of money from an unlikely group of investors — health systems. More providers are ...

This collaboration will use 10x Genomics' Chromium GEM-X technology for single-cell analysis. Launched in 2024, the GEM-X technology architecture delivers superior sensitivity, throughput ...

Landmark single-cell dataset of one billion cells will be used to train new AI models to advance understanding of cellular ...

On Wednesday, 10x Genomics Inc (NASDAQ:TXG) reported a fourth-quarter EPS loss of $(0.40), missing the consensus estimate of ...

BioSkryb Genomics, a Durham company focused on single-cell and ultra-low input multiomics, has introduced a new service called ResolveSEQ MRD, which allows more detailed classification and ...

JPMorgan analyst Rachel Vatnsdal lowered the firm’s price target on 10x Genomics (TXG) to $12 from $14 and keeps a Neutral rating on the shares ...

Leerink downgraded 10x Genomics (TXG) to Market Perform from Outperform with a price target of $12, down from $25. Despite having the market ...

The Chan Zuckerberg Initiative (CZI), in collaboration with partners 10x Genomics, Ultima Genomics, and a group of leading ...

A type of aggressive, treatment-resistant brain tumor has a distinct population of immune cells that support its growth, a ...

Today, the Chan Zuckerberg Initiative (CZI) launched the Billion Cells Project, an effort to generate an unprecedented one ...